NIZO is delighted to partner with Microbiome Drug Development Summit Europe 2018 taking place in Paris, France between 29 January – 1 February. See how leading researchers are addressing unique scientific and product developmental challenges when bringing about a new age of microbiome-based therapeutics.
The Microbiome Drug Development Summit Europe is the only end-to-end meeting designed exclusively for industry leaders to help accelerate the precise translation of microbiome R&D from disease causation into safe, effective and commercially scalable therapeutic products.
More about the Microbiome Drug Development Summit Europe
Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnected community of symbiotic, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human microbiome on human health and disease, recent efforts have sought to harness this research to create microbiome-based therapeutics.
Situated at the heart of therapeutic R&D, the Microbiome Drug Development Summit kick starts 2018, once again to help large pharma, biotech and academic institutions accelerate the discovery, clinical development of safe, effective and commercially scalable microbiome therapeutics across a broad range of disease indications.
Set to tackle the greatest scientific, regulatory, clinical, manufacturing and commercialization challenges across the entire drug development value chain, Microbiome Drug Development Summit Europe will showcase leading industry case studies focused on enhancing the application of novel technologies to standardise results, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products.